Save money and time, get standardized analysis
Analyses from the same vendor for 19 different EU countries
We will help you navigate through the challenges of reimbursement and funding for medical devices and in-vitro diagnostics in Europe
MTRC is a unique provider of Pan-European reimbursement services and products for Med Tech and IVD industry
MTRC is a unique provider of Pan-European reimbursement services and products for Med Tech and IVD industry
Scope
Coding, payment mechanism tariffs
Countries
19 EU
Pricing
On request
Availability
On-demand
Scope
Pathway to create or improve reimbursement situation
Countries
14 EU
Pricing
On request
Availability
On-demand
Scope
General introductory online course on EU market access and country-specific online seminars
Countries
10 EU
Pricing
From €490
Availability
Off-the-shelf
Scope
One day, on-site training on key aspects of market access
Countries
14 EU
Pricing
On request
Availability
On-demand
Scope
Coding, payment mechanism tariffs for a specific procedure
Countries
11 EU
Pricing
On request
Availability
Off-the-shelf
Why us?
Pharma approach is put aside
Work with a company truly specialized in medical devices and diagnostics
Getting results instantly (reports) or within 4-8 weeks (services)
Make business decisions quickly
13 out of top-30 companies choose MTRC for reimbursement support
Work with a provider who understands industry’s needs
More than 110 projects accomplished during the last year
Work with a provider who has experience in your field
Team of 15 specialists in 6 countries
Work with a provider with a Pan-European capacity
More than 200 internal instructions and protocols
Be sure about quality of the results
To stay up-to-date, we daily monitor developments of reimbursement systems in Europe
Subscribe to our newsletter to get updates every 2nd week
23 Jul 2019
This free webinar provides an overview of typical challenges of market access function (reimbursement, funding, evidence development) and how these challenges can be addressed using MTRC best practices. It is useful for those working in the market access capacity in the medical device industry.
16
Aug 2019
The HTA center of Swedish Västra Götaland region has published a report for gene expression profiles to guide adjuvant chemotherapy in luminal, HER2-negative breast cancer. It was concluded that withholding adjuvant chemotherapy in breast cancer patients with intermediate clinical risk of recurrence and low/intermediate risk according to a gene expression assay, compared with providing chemotherapy, probably results in little or no difference in overall survival within nine years and can probably not exclude a small increased risk of recurrence.
15
Aug 2019
Domestic use of motor-driven moving splints (continuous passive motion, CPM) after interventions at the knee or shoulder joint remains covered by statutory health insurance. This has been determined by the G-BA (the Federal Joint Committee).
14
Aug 2019
The Danish National Board of Health sent a new national clinical guideline for treatment with oxygen in the acutely ill adult patient in consultation.
13
Aug 2019
NHSX has officially launched in July 2019 bringing together teams from the Department of Health and Social Care and NHS England and NHS Improvement, to lead the largest digital health and social care transformation program in the world. With an investment of more than £1 billion pounds a year nationally and a significant additional spend locally, NHSX has been created to give staff and citizens the technology they need.
Visit MARKET ACCESS INSIDER - the first YouTube channel on market access
Our two core services are the provision of off-the-shelf and on-demand reimbursement analysis and the development of reimbursement strategy for medical devices in 19 European countries
| Analysis | |
Reimbursement
|
National fundingWillingness to pay for technology, based on:
|
| Strategy |
Reimbursement strategyPathway to get reimbursement:
|
Check our specific propositions for: Med Tech industry, IVD industry, Investors
Our services cover 19 European countries, including Austria, Belgium, Czech Republic, Denmark, England, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, Switzerland and Turkey
We provide services for major types of medical technologies
|
Implantable devices |
Interventional procedures |
Non-interventional procedures |
In-vitro diagnostic tests |
Medical aids |
|
Our analytical team has worked on hundreds of reimbursement projects within different clinical and technological areas, including heart valve replacement, minimally invasive and open heart surgery, coronary, cerebral and peripheral stenting, coronary diagnostic and imaging techniques (fractional flow reserve, intravascular ultrasound), coronary, cerebral and peripheral vascular thrombectomy, implantable and extracorporeal ventricular assist devices, clinic- and home-based dialysis, extracorporeal membrane oxygenation, apheresis, obesity surgery, hernia and reconstruction surgery, tissue products and skin reconstruction surgery, negative wound pressure therapy and medical bandages, neurostimulators for different indications, cell therapy, rehabilitation devices, devices for minimally invasive and open spine surgery, embolization procedures, glucose monitoring, use of fusidial markers, radiotherapy, endoscopy and more
|
Confidence in results
We have established numerous procedures and services to ensure the high relevance and precision of our analysis in order to successfully guide your business decisions:
- Standard Operating Procedures and Work Instructions
- Access to official coding and DRG manuals, tariff lists and grouping software
- A team comprised of experienced Clinical Coders with a medical background
- Quick access to health authorities to address uncertainties
- Ongoing research program to get insights from payer and provider interviews
- All reports are reviewed by the CEO before release
Check out our database of the off-the-shelf reimbursement reports for medical technologies in 11 European countries
Released reports:
|
Ongoing reports:
|